4 Benefits of Decentralized Clinical Trials

Decentralized clinical trials (DCTs) are the recent advancements in clinical trials that enable trial-related activities to take place at participants' homes or other convenient locations. This has eliminated the need for participants to visit the research sites. The U.S. Food and Drug Administration (FDA) is advancing the use of DCTs for drugs, biologics, and devices to be conducted outside traditional clinical trial sites.

In this article:

• 1. Overview of Decentralized Clinical Trials
• 2. What sets Decentralized clinical trials apart from traditional clinical trials?
• 3. Benefit 1: Increased Patient Access and Participation
• 4. Benefit 2: Improved Data Quality and Accuracy
• 5. Benefit 3: Greater Efficiency and Reduced Costs
• 6.Benefit 4: Enhanced Patient Experience and Convenience
• 7.The Outlook
• 8.FAQs

In fully decentralized clinical trials, all activities occur at locations other than traditional trial sites. However, this should not be confused with hybrid DCTs, as in the latter, trial participants are also required to visit the traditional clinical trial sites in person for some trial-related activities.

Examples of decentralized trials include conducting laboratory tests at local facilities instead of research centers and performing clinical follow-up visits in participants' homes via telemedicine.

While DCTs started way back in 2011, the momentum picked up during the COVID-19 pandemic, which boosted the adoption of remote trial activities and enhanced patient engagement.

This novel approach to conducting trials reduces participation barriers and helps diversify the trial participants pool. It also enhances accessibility for individuals with rare diseases or mobility issues. DCT has thus emerged as an effective way to advance drug development, particularly in areas with significant medical needs, ultimately leading to more treatment options and better patient outcomes.

Trial activities can be conducted at participants' homes or local facilities.
Utilizes telemedicine for remote consultations and follow-ups.

Reduces the need for frequent visits to centralized trial sites.
Enhances accessibility for participants with mobility issues or rare diseases.

Employs digital tools and wearable devices for real-time data collection.
Uses online platforms for patient monitoring and communication.

Easier to include a broader and more diverse participant pool.
Reduces geographic and logistical barriers to participation.

Potentially lowers costs by minimizing the need for physical infrastructure and travel.
Streamlines trial processes through digital management.

Participants are required to visit designated research sites.
Physical presence is needed for most trial-related activities.

Frequent travel to trial sites can be burdensome.
Limited accessibility for those with mobility constraints or living in remote areas.

Relies more on in-person visits and less on digital tools.
Less emphasis on remote data collection and monitoring.

Geographic and logistical constraints can limit participant diversity.
Often includes participants who live near trial sites.

Requires significant investment in physical infrastructure and travel expenses.
Involves higher operational costs for site management and staffing.

DCTs can enhance participant recruitment and retention by accommodating individuals regardless of their location or work schedule. This approach reduces the cost and time burdens associated with traveling to trial sites for numerous study visits, making the process more convenient and efficient for participants.

Traditional trials often struggle to recruit participants from different ethnic, socio-economic, and geographical backgrounds due to logistical challenges. This often creates obstacles to basic medical care and hinder participation in clinical trials for marginalized groups. Decentralized trials could help bridge this gap and improve access to research for these populations.

This diversity is also crucial for understanding how different populations respond to treatments, leading to more effective and inclusive healthcare solutions.

These clinical trials utilize various technologies to make remote participation possible. These include telemedicine platforms, mobile health apps, wearable devices, electronic patient-reported outcomes (ePROs), and remote monitoring systems. By leveraging these technologies, researchers can gather real-time data and gain deeper insights into participants' health conditions. This approach enhances the overall understanding of participants' well-being throughout the trial.

These remote clinical trials have the potential to enhance the quality and precision of trial data by minimizing the chances of human error linked with manual data entry. This improvement in data collection can lead to more dependable trial outcomes and lower the risk of bias. According to a survey among clinical research experts, 72% expressed confidence that decentralized trials could elevate the quality of trial data by decreasing human error and refining the standardization of data collection and analysis.

Incorporating decentralized methods can greatly enhance trial efficiency and decrease expenses in several ways. It streamlines the processes of consent and enrollment, making participation more convenient for individuals. Offering interventions remotely alleviates the time and travel constraints participants often face.

Additionally, decentralized approaches allow for remote measurement of outcomes, further reducing the need for in-person visits. This not only speeds up the trial process but also minimizes the need for protocol adjustments. Furthermore, by implementing practices that bring research directly to the participant help enhance overall engagement and satisfaction, making clinical trials become more participant-centered.

Since these trials harness digital technologies for real-time data collection and analysis, they offer a significant advantage in safety monitoring. This approach allows for more frequent and efficient surveillance of patient safety, leading to earlier detection of adverse events and quicker responses to potential risks. As a result, patient safety is significantly improved.

Remote monitoring also has the potential to enhance the safety of clinical trial participants. By enabling more frequent and efficient safety monitoring, DCTs ensure that patients receive timely interventions and that risks are promptly addressed, which ultimately contributes to better overall safety outcomes.

While decentralized methods show promise, remote screening/enrollment and initial evaluation require further refinement to gauge their effectiveness. Challenges like participants' lack of digital access and concerns about online security need to be addressed. However, this might add to the workload of research coordinators.

DCTs represent the future of medical research and have the potential to transform the landscape. They offer the flexibility of conducting trials virtually anywhere, anytime, offering a cost-effective and time-efficient means to expedite the drug development process. Moreover, they enhance access to medical research, mitigate the risk of data loss or contamination, and enhance the accuracy of collected data.

Life sciences companies looking to identify clinical investigators or gain some brilliant insights into the clinical trial landscape can greatly benefit from konectar professional services. To know more, request a demo of konectar today!